Clotilde Mannoury la Cour
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Clotilde Mannoury la Cour has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Claudette Boni
Institut National de la Santé et de la Recherche Médicale U288, Neuropsychopharmacologie Moléculaire, Cellulaire et Fonctionnelle, Faculté de Médecine Pitié-Salpêtrière, 75634 Paris Cedex 13, France, and
1 shared publication- Klaus-Peter Lesch
Division of Molecular Psychiatry, Center of Mental Health, University Hospital Würzburg, Würzburg, Germany
1 shared publication Laurence Lanfumey
Institut National de la Santé et de la Recherche Médicale U288, Neuropsychopharmacologie Moléculaire, Cellulaire et Fonctionnelle, Faculté de Médecine Pitié-Salpêtrière, 75634 Paris Cedex 13, France, and
1 shared publicationMichel Hamon
Institut National de la Santé et de la Recherche Médicale U288, Neuropsychopharmacologie Moléculaire, Cellulaire et Fonctionnelle, Faculté de Médecine Pitié-Salpêtrière, 75634 Paris Cedex 13, France, and
1 shared publicationNaı̈ma Hanoun
Institut National de la Santé et de la Recherche Médicale U288, Neuropsychopharmacologie Moléculaire, Cellulaire et Fonctionnelle, Faculté de Médecine Pitié-Salpêtrière, 75634 Paris Cedex 13, France, and
1 shared publication
Latest Publications
- 15 March 2001
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 21 (6) , 2178-2185
Functional Consequences of 5-HT Transporter Gene Disruption on 5-HT1AReceptor-Mediated Regulation of Dorsal Raphe and Hippocampal Cell Activity
The consequences of the absence of 5-HT reuptake on the functional properties of 5-HT1A receptors were examined in the dorsal raphe nucleus and the hippocampus of knock-out mice lacking the serotonin transporter (5-HTT). Extracellular recordings showed that application of selective 5-HT reuptake inhibitors such as paroxetine and citalopram onto brainstem slices resulted in a concentration-dependent inhibition of 5-HT neuron firing in the dorsal raphe nucleus of wild-type 5-HTT+/+ mice, but not 5-HTT−/− mutants. By contrast, the 5-HT1A receptor agonists ipsapirone and 5-carboxamidotryptamine inhibited the discharge in both groups. However, the potency of these agonists was markedly decreased (by ∼55- and ∼6-fold, respectively) in 5-HTT−/− compared with 5-HTT+/+ animals. Similarly, intracellular recordings showed that the potency of 5-carboxamidotryptamine to hyperpolarize 5-HT neurons in the dorsal raphe nucleus was significantly lower in 5-HTT−/− than in 5-HTT+/+ animals. These data contrasted with those obtained with hippocampal slices in which 5-carboxamidotryptamine was equipotent to hyperpolarize CA1 pyramidal neurons in both mutant and wild-type mice. As expected from their mediation through 5-HT1A receptors, the effects of ipsapirone and 5-carboxamidotryptamine were competitively inhibited by the selective 5-HT1A antagonist WAY 100635 in both groups. These data showed that 5-HTT gene knock-out induced a marked desensitization of 5-HT1A autoreceptors in the dorsal raphe nucleus without altering postsynaptic 5-HT1A receptor functioning in the hippocampus. Similarities between these changes and those evoked by chronic treatment with 5-HT reuptake inhibitors emphasize the existence of regional differences in 5-HT1A receptor regulatory mechanisms.
- 15 March 2001
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 21 (6) , 2178-2185
Functional Consequences of 5-HT Transporter Gene Disruption on 5-HT1AReceptor-Mediated Regulation of Dorsal Raphe and Hippocampal Cell Activity
The consequences of the absence of 5-HT reuptake on the functional properties of 5-HT1A receptors were examined in the dorsal raphe nucleus and the hippocampus of knock-out mice lacking the serotonin transporter (5-HTT). Extracellular recordings showed that application of selective 5-HT reuptake inhibitors such as paroxetine and citalopram onto brainstem slices resulted in a concentration-dependent inhibition of 5-HT neuron firing in the dorsal raphe nucleus of wild-type 5-HTT+/+ mice, but not 5-HTT−/− mutants. By contrast, the 5-HT1A receptor agonists ipsapirone and 5-carboxamidotryptamine inhibited the discharge in both groups. However, the potency of these agonists was markedly decreased (by ∼55- and ∼6-fold, respectively) in 5-HTT−/− compared with 5-HTT+/+ animals. Similarly, intracellular recordings showed that the potency of 5-carboxamidotryptamine to hyperpolarize 5-HT neurons in the dorsal raphe nucleus was significantly lower in 5-HTT−/− than in 5-HTT+/+ animals. These data contrasted with those obtained with hippocampal slices in which 5-carboxamidotryptamine was equipotent to hyperpolarize CA1 pyramidal neurons in both mutant and wild-type mice. As expected from their mediation through 5-HT1A receptors, the effects of ipsapirone and 5-carboxamidotryptamine were competitively inhibited by the selective 5-HT1A antagonist WAY 100635 in both groups. These data showed that 5-HTT gene knock-out induced a marked desensitization of 5-HT1A autoreceptors in the dorsal raphe nucleus without altering postsynaptic 5-HT1A receptor functioning in the hippocampus. Similarities between these changes and those evoked by chronic treatment with 5-HT reuptake inhibitors emphasize the existence of regional differences in 5-HT1A receptor regulatory mechanisms.